http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 03 Mar 2026 17:35:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aurinia+Pharmaceuticals+++For%3A+Feb+27++Filed+by%3A+TANG+KEVIN/26104179.html si-local-file:///var/storage/secattach/20260303/26104179.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aurinia+Pharmaceuticals+++For%3A+Feb+27++Filed+by%3A+TANG+KEVIN/26104179.html Tue, 03 Mar 2026 17:35:00 -0500 AUPH O.00888987 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aurinia+Pharmaceuticals+++For%3A+Feb+27++Filed+by%3A+TANG+KEVIN/26104179.html si-local-file:///var/storage/secattach/20260303/26104179.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aurinia+Pharmaceuticals+++For%3A+Feb+27++Filed+by%3A+TANG+KEVIN/26104179.html Tue, 03 Mar 2026 17:35:00 -0500 AUPH O.00888987 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Aurinia+Pharmaceuticals++++++++++++++++Filed+by%3A+TANG+CAPITAL+MANAGEMENT+LLC/26104082.html si-local-file:///var/storage/secattach/20260303/26104082.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Aurinia+Pharmaceuticals++++++++++++++++Filed+by%3A+TANG+CAPITAL+MANAGEMENT+LLC/26104082.html Tue, 03 Mar 2026 17:30:00 -0500 AUPH O.00888987 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Aurinia+Pharmaceuticals++++++++++++++++Filed+by%3A+TANG+CAPITAL+MANAGEMENT+LLC/26104082.html si-local-file:///var/storage/secattach/20260303/26104082.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Aurinia+Pharmaceuticals++++++++++++++++Filed+by%3A+TANG+CAPITAL+MANAGEMENT+LLC/26104082.html Tue, 03 Mar 2026 17:30:00 -0500 AUPH O.00888987 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aurinia+Pharmaceuticals+++For%3A+Feb+27++Filed+by%3A+Greenleaf+Peter/26101634.html si-local-file:///var/storage/secattach/20260303/26101634.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aurinia+Pharmaceuticals+++For%3A+Feb+27++Filed+by%3A+Greenleaf+Peter/26101634.html Tue, 03 Mar 2026 16:18:00 -0500 AUPH O.00888987 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aurinia+Pharmaceuticals+++For%3A+Feb+27++Filed+by%3A+Greenleaf+Peter/26101634.html si-local-file:///var/storage/secattach/20260303/26101634.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aurinia+Pharmaceuticals+++For%3A+Feb+27++Filed+by%3A+Greenleaf+Peter/26101634.html Tue, 03 Mar 2026 16:18:00 -0500 AUPH O.00888987 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aurinia+Pharmaceuticals+++For%3A+Feb+27++Filed+by%3A+Miller+Joseph+M/26101648.html si-local-file:///var/storage/secattach/20260303/26101648.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aurinia+Pharmaceuticals+++For%3A+Feb+27++Filed+by%3A+Miller+Joseph+M/26101648.html Tue, 03 Mar 2026 16:18:00 -0500 AUPH O.00888987 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aurinia+Pharmaceuticals+++For%3A+Feb+27++Filed+by%3A+Miller+Joseph+M/26101648.html si-local-file:///var/storage/secattach/20260303/26101648.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aurinia+Pharmaceuticals+++For%3A+Feb+27++Filed+by%3A+Miller+Joseph+M/26101648.html Tue, 03 Mar 2026 16:18:00 -0500 AUPH O.00888987 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aurinia+Pharmaceuticals+++For%3A+Feb+27++Filed+by%3A+Keenan+Greg/26101660.html si-local-file:///var/storage/secattach/20260303/26101660.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aurinia+Pharmaceuticals+++For%3A+Feb+27++Filed+by%3A+Keenan+Greg/26101660.html Tue, 03 Mar 2026 16:18:00 -0500 AUPH O.00888987 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aurinia+Pharmaceuticals+++For%3A+Feb+27++Filed+by%3A+Keenan+Greg/26101660.html si-local-file:///var/storage/secattach/20260303/26101660.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aurinia+Pharmaceuticals+++For%3A+Feb+27++Filed+by%3A+Keenan+Greg/26101660.html Tue, 03 Mar 2026 16:18:00 -0500 AUPH O.00888987 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aurinia+Pharmaceuticals+++For%3A+Feb+27++Filed+by%3A+Robertson+Stephen+P./26101678.html si-local-file:///var/storage/secattach/20260303/26101678.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aurinia+Pharmaceuticals+++For%3A+Feb+27++Filed+by%3A+Robertson+Stephen+P./26101678.html Tue, 03 Mar 2026 16:18:00 -0500 AUPH O.00888987 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aurinia+Pharmaceuticals+++For%3A+Feb+27++Filed+by%3A+Robertson+Stephen+P./26101678.html si-local-file:///var/storage/secattach/20260303/26101678.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aurinia+Pharmaceuticals+++For%3A+Feb+27++Filed+by%3A+Robertson+Stephen+P./26101678.html Tue, 03 Mar 2026 16:18:00 -0500 AUPH O.00888987 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aurinia+Pharmaceuticals+++For%3A+Feb+27++Filed+by%3A+Donley+Matthew+Maxwell/26101679.html si-local-file:///var/storage/secattach/20260303/26101679.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aurinia+Pharmaceuticals+++For%3A+Feb+27++Filed+by%3A+Donley+Matthew+Maxwell/26101679.html Tue, 03 Mar 2026 16:18:00 -0500 AUPH O.00888987 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aurinia+Pharmaceuticals+++For%3A+Feb+27++Filed+by%3A+Donley+Matthew+Maxwell/26101679.html si-local-file:///var/storage/secattach/20260303/26101679.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aurinia+Pharmaceuticals+++For%3A+Feb+27++Filed+by%3A+Donley+Matthew+Maxwell/26101679.html Tue, 03 Mar 2026 16:18:00 -0500 AUPH O.00888987 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Aurinia+Pharmaceuticals+++For%3A+Feb+26/26063653.html si-local-file:///var/storage/secattach/20260226/26063653.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Aurinia+Pharmaceuticals+++For%3A+Feb+26/26063653.html Thu, 26 Feb 2026 06:08:00 -0500 AUPH O.00888987 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Aurinia+Pharmaceuticals+++For%3A+Feb+26/26063653.html si-local-file:///var/storage/secattach/20260226/26063653.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Aurinia+Pharmaceuticals+++For%3A+Feb+26/26063653.html Thu, 26 Feb 2026 06:08:00 -0500 AUPH O.00888987 http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++Aurinia+Pharmaceuticals+++For%3A+Dec+31/26063667.html si-local-file:///var/storage/secattach/20260226/26063667.html http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++Aurinia+Pharmaceuticals+++For%3A+Dec+31/26063667.html Thu, 26 Feb 2026 06:08:00 -0500 AUPH O.00888987 http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++Aurinia+Pharmaceuticals+++For%3A+Dec+31/26063667.html si-local-file:///var/storage/secattach/20260226/26063667.html http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++Aurinia+Pharmaceuticals+++For%3A+Dec+31/26063667.html Thu, 26 Feb 2026 06:08:00 -0500 AUPH O.00888987 http://www.streetinsider.com/Earnings/Aurinia+Pharmaceuticals+%28AUPH%29+Tops+Q4+EPS+by+%241.38%2C+provides+guidance/26063349.html <p>Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q4 EPS of $1.53, $1.38 better than the analyst estimate of $0.15. Revenue for the quarter came in at $77.1 million versus the consensus estimate of $74.41 million.</p><p><strong>GUIDANCE:</strong></p><p>Aurinia Pharmaceuticals sees FY2026 revenue of $315-325 million.</p><p>For earnings history and earnings-related data on Aurinia Pharmaceuticals (AUPH) <a href="http://www.streetinsider.com/ec_earnings.php?q=AUPH">click here</a>.</p> http://www.streetinsider.com/Earnings/Aurinia+Pharmaceuticals+%28AUPH%29+Tops+Q4+EPS+by+%241.38%2C+provides+guidance/26063349.html Thu, 26 Feb 2026 06:06:04 -0500 AUPH http://www.streetinsider.com/Guidance/Aurinia+Pharmaceuticals+%28AUPH%29+Tops+Q4+EPS+by+%241.38%2C+provides+guidance/26063349.html <p>Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q4 EPS of $1.53, $1.38 better than the analyst estimate of $0.15. Revenue for the quarter came in at $77.1 million versus the consensus estimate of $74.41 million.</p><p><strong>GUIDANCE:</strong></p><p>Aurinia Pharmaceuticals sees FY2026 revenue of $315-325 million.</p><p>For earnings history and earnings-related data on Aurinia Pharmaceuticals (AUPH) <a href="http://www.streetinsider.com/ec_earnings.php?q=AUPH">click here</a>.</p> http://www.streetinsider.com/Guidance/Aurinia+Pharmaceuticals+%28AUPH%29+Tops+Q4+EPS+by+%241.38%2C+provides+guidance/26063349.html Thu, 26 Feb 2026 06:06:04 -0500 AUPH http://www.streetinsider.com/Press+Releases/Aurinia+Pharmaceuticals+Reports+Financial+Results+for+the+Three+and+Twelve+Months+Ended+December+31%2C+2025+and+Provides+Update+on+Recent+Business+Progress/26063106.html <p class="bwalignc"> <i>Full Year 2025 LUPKYNIS Sales Grew 25%</i> </p><p class="bwalignc"> <i>Announces LUPKYNIS Sales Guidance for 2026 of $305 Million to $315 Million</i> </p> <p> ROCKVILLE, Md. &amp; EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three and twelve months ended December 31, 2025 and provided an update on recent business progress. </p><p> <b>Financial Results</b> </p><ul class="bwlistdisc"> <li> <b>Total Revenue: </b>For the three and twelve months ended December 31, 2025, total revenue was $77.1 million and $283.1 million, up 29% and 20%, respectively, compared to $59.9 million and $235.1 million, respectively, for the same periods of 2024. <ul class="bwlistcircle"> <li> <b>Net Product Sales: </b>For the http://www.streetinsider.com/Press+Releases/Aurinia+Pharmaceuticals+Reports+Financial+Results+for+the+Three+and+Twelve+Months+Ended+December+31%2C+2025+and+Provides+Update+on+Recent+Business+Progress/26063106.html Thu, 26 Feb 2026 06:00:00 -0500 AUPH O.00888987 http://www.streetinsider.com/Press+Releases/Aurinia+Pharmaceuticals+Reports+Financial+Results+for+the+Three+and+Twelve+Months+Ended+December+31%2C+2025+and+Provides+Update+on+Recent+Business+Progress/26063106.html <p class="bwalignc"> <i>Full Year 2025 LUPKYNIS Sales Grew 25%</i> </p><p class="bwalignc"> <i>Announces LUPKYNIS Sales Guidance for 2026 of $305 Million to $315 Million</i> </p> <p> ROCKVILLE, Md. &amp; EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three and twelve months ended December 31, 2025 and provided an update on recent business progress. </p><p> <b>Financial Results</b> </p><ul class="bwlistdisc"> <li> <b>Total Revenue: </b>For the three and twelve months ended December 31, 2025, total revenue was $77.1 million and $283.1 million, up 29% and 20%, respectively, compared to $59.9 million and $235.1 million, respectively, for the same periods of 2024. <ul class="bwlistcircle"> <li> <b>Net Product Sales: </b>For the http://www.streetinsider.com/Press+Releases/Aurinia+Pharmaceuticals+Reports+Financial+Results+for+the+Three+and+Twelve+Months+Ended+December+31%2C+2025+and+Provides+Update+on+Recent+Business+Progress/26063106.html Thu, 26 Feb 2026 06:00:00 -0500 AUPH O.00888987 http://www.streetinsider.com/Business+Wire/Aurinia+Pharmaceuticals+Reports+Financial+Results+for+the+Three+and+Twelve+Months+Ended+December+31%2C+2025+and+Provides+Update+on+Recent+Business+Progress/26063106.html <p class="bwalignc"> <i>Full Year 2025 LUPKYNIS Sales Grew 25%</i> </p><p class="bwalignc"> <i>Announces LUPKYNIS Sales Guidance for 2026 of $305 Million to $315 Million</i> </p> <p> ROCKVILLE, Md. &amp; EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three and twelve months ended December 31, 2025 and provided an update on recent business progress. </p><p> <b>Financial Results</b> </p><ul class="bwlistdisc"> <li> <b>Total Revenue: </b>For the three and twelve months ended December 31, 2025, total revenue was $77.1 million and $283.1 million, up 29% and 20%, respectively, compared to $59.9 million and $235.1 million, respectively, for the same periods of 2024. <ul class="bwlistcircle"> <li> <b>Net Product Sales: </b>For the http://www.streetinsider.com/Business+Wire/Aurinia+Pharmaceuticals+Reports+Financial+Results+for+the+Three+and+Twelve+Months+Ended+December+31%2C+2025+and+Provides+Update+on+Recent+Business+Progress/26063106.html Thu, 26 Feb 2026 06:00:00 -0500 AUPH O.00888987 http://www.streetinsider.com/Business+Wire/Aurinia+Pharmaceuticals+Reports+Financial+Results+for+the+Three+and+Twelve+Months+Ended+December+31%2C+2025+and+Provides+Update+on+Recent+Business+Progress/26063106.html <p class="bwalignc"> <i>Full Year 2025 LUPKYNIS Sales Grew 25%</i> </p><p class="bwalignc"> <i>Announces LUPKYNIS Sales Guidance for 2026 of $305 Million to $315 Million</i> </p> <p> ROCKVILLE, Md. &amp; EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three and twelve months ended December 31, 2025 and provided an update on recent business progress. </p><p> <b>Financial Results</b> </p><ul class="bwlistdisc"> <li> <b>Total Revenue: </b>For the three and twelve months ended December 31, 2025, total revenue was $77.1 million and $283.1 million, up 29% and 20%, respectively, compared to $59.9 million and $235.1 million, respectively, for the same periods of 2024. <ul class="bwlistcircle"> <li> <b>Net Product Sales: </b>For the http://www.streetinsider.com/Business+Wire/Aurinia+Pharmaceuticals+Reports+Financial+Results+for+the+Three+and+Twelve+Months+Ended+December+31%2C+2025+and+Provides+Update+on+Recent+Business+Progress/26063106.html Thu, 26 Feb 2026 06:00:00 -0500 AUPH O.00888987 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aurinia+Pharmaceuticals+++For%3A+Feb+20++Filed+by%3A+Donley+Matthew+Maxwell/26043274.html si-local-file:///var/storage/secattach/20260223/26043274.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aurinia+Pharmaceuticals+++For%3A+Feb+20++Filed+by%3A+Donley+Matthew+Maxwell/26043274.html Mon, 23 Feb 2026 16:08:00 -0500 AUPH O.00888987